Prosidion Limited

Andrew J Pospisilik

Hans-Ulrich Demuth

Konrad Glund

Kerstin Kuehn-Wache

The present invention discloses methods for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic &#x3b2;-cells, to cause differentiation of pancreatic epithelial cells into insulin producing &#x3b2;-cells, to improve muscle sensitivity to insulin and other weight control efforts by the chronic oral administration of a DP IV-inhibitor. The administration causes the active form of GLP-1 and other non-nutrient stimulated growth hormones to remain biologically active longer under physiological conditions. The extended presence of such hormones, in particular in the pancreatic tissue can also facilitate differentiation and regeneration of the &#x3b2;-cells already present that are in need of repair.

Growing community of inventors

Vancouver, Canada

Andrew J Pospisilik